ArticleJournal of translational medicine2025
A mitochondria-related gene-based signature predicts pancreatic ductal adenocarcinoma clinical outcome and revealed CAMK2A/THEM4 regulates progression phenotypes and mitophagy in vivo and in vitro.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- UBA6 serves as a prognostic biomarker and promotes tumor progression in pancreatic ductal adenocarcinoma.Translational cancer research · 2026Article
- Acyl-CoA thioesterases and their derived lipid mediators: linking Acyl-CoA metabolic reprogramming to the tumor microenvironment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited available prognostic tools. There is a need to develop robust molecular signatures to improve risk stratification and identify potential therapeutic targets.
methodsA 12-gene mitochondrial-related prognostic signature was developed using machine learning. The performance was compared with signatures developed using other algorithms and published signatures. The detailed synergistic role and molecular mechanism of signature gene CAMK2A and THEM4 was investigated. Additionally, an immunohistochemical (IHC) microarray and in vivo xenograft model was performed to evaluate the prognostic utility of candidate genes.
resultsThe prognostic signature effectively stratified patients into high- and low-risk groups with significantly different survival outcomes (median OS: 15.4 vs. 24.1 months, p < 0.0001). It demonstrated robust predictive accuracy across datasets and outperformed 101 other machine learning-based signatures as well as previously reported models. High-risk samples showed enrichment in cancer-related pathways and unique adaptive drug profiles. Single-cell sequencing data indicated that the signature reflects immune cell infiltration and cell-cell interaction heterogeneity. Functional experiments revealed that CAMK2A suppresses PDAC progression by impairing mitochondrial function-reducing membrane potential, ATP production, and ROS levels-and facilitating THEM4 release from mitochondria. THEM4, which is downregulated in PDAC, inhibited tumor growth by suppressing AKT phosphorylation (p < 0.01). THEM4 knockdown accelerated in vivo tumor growth. Clinically, combining THEM4 and CAMK2A expression improved prognostic performance compared to either biomarker alone.
conclusionsThis study establishes a mitochondria-driven prognostic model for PDAC and identifies the CAMK2A-THEM4-AKT axis as a novel therapeutic target. To our knowledge, this is the first pancreatic cancer signature that investigates the synergistic effect of candidate genes, offering both prognostic and mechanistic insights into PDAC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.